Gilead Stock Surges on Strong Q2, Raised Guidance

Gilead Sciences reported strong Q2 2025 results, with adjusted EPS of $2.01 and revenues of $7.1 billion, driven by robust HIV drug sales, especially Biktarvy and Descovy. The company raised its full-year guidance, projecting product sales of $28.3–$28.7 billion and adjusted EPS of $7.95–$8.25, citing continued strength in its HIV franchise and early success with the new twice-yearly PrEP shot, Yeztugo. Overall product sales excluding Veklury rose by 4%, while liver disease portfolio sales fell and Veklury sales declined sharply. Gilead executives voiced confidence in overcoming future access challenges for PrEP products amid regulatory uncertainties. The strong quarter drove Gilead's stock to its highest level since 2015, making it a top performer in the S&P 500 and Nasdaq 100. Analysts responded positively, highlighting optimism about the company's strategy and pipeline momentum.